Imugene Ltd
IMU
Company Profile
Business description
Imugene Ltd is a clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumours. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.
Contact
4-6 Bligh Street
Suite 12.01, Level 12
SydneyNSW2000
AUST: +61 294230881
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
5
Stocks News & Analysis
stocks
Margins have bottomed for ASX listed consumer goods company
Impact of tariffs have been priced in.
stocks
SpaceX rally continues, expanding sky-high valuations
SpaceX has risen 50% from its IPO price to become the second-most-expensive stock under Morningstar’s coverage.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,031.20 | 9.40 | 0.10% |
| CAC 40 | 8,400.11 | 21.03 | -0.25% |
| DAX 40 | 25,139.69 | 153.87 | 0.62% |
| Dow JONES (US) | 51,713.30 | 148.60 | 0.29% |
| FTSE 100 | 10,437.85 | 74.58 | 0.72% |
| HKSE | 23,768.52 | 156.29 | -0.65% |
| NASDAQ | 26,167.45 | 350.48 | -1.32% |
| Nikkei 225 | 72,353.96 | 1,103.90 | 1.55% |
| NZX 50 Index | 13,446.05 | 49.58 | -0.37% |
| S&P 500 | 7,476.34 | 24.24 | -0.32% |
| S&P/ASX 200 | 8,816.10 | 14.20 | 0.16% |
| SSE Composite Index | 4,163.10 | 72.62 | 1.78% |